Join our
Investor Newsletter

To receive Investor News as it is released please sign up

News Releases

Renalytix Reports Financial Results for Q1 FY2024

November 14, 2023
RNS Number : 3099T Renalytix PLC 14 November 2023   Renalytix plc ("Renalytix" or the "Company")   Renalytix Reports Financial Results for First Quarter of Fiscal Year 2024   LONDON and SALT LAKE CITY , November 14, 2023   - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial

Notice of Results

November 7, 2023
RNS Number : 5522S Renalytix PLC 07 November 2023     Renalytix plc ("Renalytix" or the "Company")   Renalytix to Report Financial Results for First Quarter Fiscal Year 2024 on November 14   LONDON and SALT LAKE CITY , November 7, 2023 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that it

Announcement of AGM and Publication of AR

October 30, 2023
RNS Number : 7470R Renalytix PLC 30 October 2023     Renalytix plc ("Renalytix" or the "Company")   Announcement of AGM and Publication of Annual Report 2023   LONDON and SALT LAKE CITY, UT   October 30, 2023 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that its Annual General Meeting

Directorate change

October 24, 2023
RNS Number : 0376R Renalytix PLC 24 October 2023   Renalytix plc ("Renalytix" or the "Company")   Directorate change   LONDON and SALT LAKE CITY -   October 24, 2023 -   Renalytix plc   (NASDAQ: RNLX) (LSE: RENX) , the first company to commercialize an FDA authorized artificial intelligence (AI)

Issue of Shares

October 17, 2023
RNS Number : 3030Q Renalytix PLC 17 October 2023   Renalytix plc ("Renalytix" or the "Company")   Issue of Shares   LONDON and SALT LAKE CITY -   October 17, 2023 -   Renalytix plc   (NASDAQ: RNLX) (LSE: RENX) , announces the repayment of $1.06 million of the Company's convertible bond, further

US Patent Office Allows Patent Claims for IP

October 6, 2023
RNS Number : 8892O Renalytix PLC 06 October 2023     Renalytix plc ("Renalytix" or the "Company")   US Patent Office Allows Patent Claims for Intellectual Property Exclusively Licensed to Renalytix   LONDON and SALT LAKE CITY -   October 6, 2023 -   Renalytix plc   (NASDAQ: RNLX) (LSE: RENX), the

Issue of Shares

October 3, 2023
RNS Number : 5660O Renalytix PLC 03 October 2023     Renalytix plc ("Renalytix" or the "Company")   Issue of Shares   LONDON and SALT LAKE CITY , October 3, 2023 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that under the Company's Employee Share Purchase Plan (the "ESPP"), 75,328 new

Medicare prices kidneyintelX.dkd at $950

October 3, 2023
RNS Number : 4486O Renalytix PLC 03 October 2023     THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED IN ARTICLE 7 OF MAR. THE PERSON RESPONSIBLE FOR ARRANGING THE RELEASE OF THIS ANNOUNCEMENT ON BEHALF OF RENALYTIX IS JAMES MCCULLOUGH , CEO. Renalytix plc ("Renalytix" or the "Company")  

Renalytix Reports Full Year Fiscal 2023 Results

September 28, 2023
RNS Number : 9254N Renalytix PLC 28 September 2023   Renalytix plc ("Renalytix" or the "Company")   Renalytix Reports Full Year Fiscal 2023 Results   LONDON and SALT LAKE CITY , September 28, 2023   - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics

Notice of Results

September 25, 2023
RNS Number : 4406N Renalytix PLC 25 September 2023     Renalytix plc ("Renalytix" or the "Company")     Renalytix to Report Financial Results for Fourth Quarter and Full Year Fiscal 2023 on September 28   LONDON and SALT LAKE CITY , September 25, 2023 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX)
Displaying 81 - 90 of 353